Left ventricular assist devices for destination therapy: a health technology assessment
Health Quality Ontario
Record ID 32016000551
English
Authors' recommendations:
For patients with end-stage heart failure who are ineligible for heart transplantation, permanent treatment with continuous-flow LVADs is effective at improving survival and quality of life compared with drug therapy. However, permanent continuous-flow devices have higher adverse event rates than drug therapy. Although it improves survival and quality of life, the device itself and the surgery to implant it are very expensive.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hqontario.ca/Portals/0/Documents/eds/ohtas/hta-lvad-1602-en.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Heart Failure
- Heart-Assist Devices
- Technology Assessment, Biomedical
- Ventricular Dysfunction, Left
Contact
Organisation Name:
Health Quality Ontario
Contact Address:
Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5
Contact Name:
EDSinfo@hqontario.ca
Contact Email:
OH-HQO_hta-reg@ontariohealth.ca
Copyright:
Health Quality Ontario (HQO)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.